Small Molecules

Particle agglomeration can compromise the clinical efficacy of pharmaceutical products and must therefore be closely controlled. This article provides practical guidance on using automated imaging for efficient agglomerate detection.

High concentration, low-viscosity, stable therapeutic protein formulations are needed to enable low-volume parental administration. This article explores how a fully automated light scattering system supports the rapid screening of small volume samples in well plates for the rapid identification of suitable biologics during early phase development.

OMNISEC measures the Critical Quality Attributes of polymeric pharmaceutical excipients with unrivalled sensitivity supporting their efficient use to formulate safe and effective pharmaceutical products.

Measurement and characterization of binding interactions between proteins and low-molecular weight (LMW) ligands are a focus of academic research and drug discovery. Isothermal titration calorimetry directly measures heat released or absorbed in a binding event, providing means for studying protein-small molecule interactions in solution without the need for labeling or immobilization. Importantly, ITC is often utilized to characterize differences in entropic and enthalpic contributions to binding of novel ligands.

In this application note we describe the use of Nanoparticle Tracking Analysis (NTA) for size and concentration measurements of drug delivery nanoparticles. In addition, by using a fluorescently tagged drug molecule, it was possible to determine how many drug delivery nanoparticles had successfully been loaded with drug molecules.

Viscosizer TD provides automated relative viscosity measurements with high reproducibility at low viscosity, to help identify molecules with abnormally high viscosity-concentration profiles at low sample concentrations as early as possible in the development pipeline

Andrew Lees lightheartedly states that he has built his career on two tenets: multivalency and being lazy. And it’s worked out well; while moonlighting as a magician, he has developed the conjugation chemistry behind some of the world's most-used vaccines. Here, he explains how he learned to combine science and magic.

Traditional pharma manufacturers are already dipping their toes in the waters of continuous processing, but what about when it comes to biopharmaceuticals?

Our experience with implementing serialization, has shown us that anti-counterfeiting is just one of its potential uses.

Antibody drug conjugates offer a great deal of potential for drug targeting, but what’s the best way of linking drugs and antibodies?